ELVN profile · all as-reported value updates

Enliven Therapeutics, Inc. (ELVN) as-reported value updates

Descriptive filing record — not investment advice. This page compares two SEC XBRL-filed values for the same fiscal period. It does not state why the values differ and is not a rating, score, or recommendation. See Disclaimer.

Reported values for the same fiscal period can differ between filings for many routine reasons: re-presentation for discontinued operations, adoption of new accounting standards, reclassifications, changes in rounding precision, and amendments. This ledger records that the filed values differ; it does not and cannot determine why. Both filings are linked below so the reader can consult the source.

Rows publish only when the later filed value differs by at least 1.0% and at least $1,000,000, after dropping differences that match under the capped trailing-zero precision rule. The delta percent is delta divided by the larger absolute filed value. Values are annual standardized facts only; metrics whose differences fall below those thresholds or match the capped precision rule are not published as rows.

Ledger table figure

Metric	FY	Earliest XBRL-filed value	Currently on file	Difference	Difference %	Label	Filing links	Notes
Stockholders' equity StockholdersEquity	2022	90,129,000 filed 2023-02-10 · 10-K	-76,825,000 filed 2025-03-13 · 10-K	-166,954,000	-185.24%	revised comparative figure	0001564590-23-001729 0000950170-25-038758	3 filed observations examined for this concept and period.
Stockholders' equity StockholdersEquity	2021	86,030,000 filed 2022-03-15 · 10-K	-42,887,000 filed 2024-03-14 · 10-K	-128,917,000	-149.85%	revised comparative figure	0001564590-22-010216 0000950170-24-031495	3 filed observations examined for this concept and period.
Net income NetIncomeLoss	2022	1,488,000 filed 2023-02-10 · 10-K	-37,662,000 filed 2024-03-14 · 10-K	-39,150,000	-103.95%	revised comparative figure	0001564590-23-001729 0000950170-24-031495	2 filed observations examined for this concept and period.
Operating income OperatingIncomeLoss	2022	730,000 filed 2023-02-10 · 10-K	-38,791,000 filed 2024-03-14 · 10-K	-39,521,000	-101.88%	revised comparative figure	0001564590-23-001729 0000950170-24-031495	2 filed observations examined for this concept and period.
Liabilities Liabilities	2022	1,830,000 filed 2023-02-10 · 10-K	10,374,000 filed 2024-03-14 · 10-K	8,544,000	+82.36%	revised comparative figure	0001564590-23-001729 0000950170-24-031495	2 filed observations examined for this concept and period.
Cash and cash equivalents CashAndCashEquivalentsAtCarryingValue	2022	88,198,000 filed 2023-02-10 · 10-K	75,536,000 filed 2024-03-14 · 10-K	-12,662,000	-14.36%	revised comparative figure	0001564590-23-001729 0000950170-24-031495	2 filed observations examined for this concept and period.
Operating cash flow NetCashProvidedByUsedInOperatingActivities	2022	-35,568,000 filed 2023-02-10 · 10-K	-32,077,000 filed 2024-03-14 · 10-K	3,491,000	+9.82%	revised comparative figure	0001564590-23-001729 0000950170-24-031495	2 filed observations examined for this concept and period.
Assets Assets	2022	91,959,000 filed 2023-02-10 · 10-K	83,298,000 filed 2024-03-14 · 10-K	-8,661,000	-9.42%	revised comparative figure	0001564590-23-001729 0000950170-24-031495	2 filed observations examined for this concept and period.